In yesterday’s Wall Street session, Lifecore Biomedical Inc. (NASDAQ:LFCR) shares traded at $7.87, down -1.63% from the previous session.
As of this writing, 2 analysts cover Lifecore Biomedical Inc. (NASDAQ:LFCR). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $9.00, we find $9.50. Given the previous closing price of $8.00, this indicates a potential upside of 18.75 percent. LFCR stock price is now -18.36% away from the 50-day moving average and 12.34% away from the 200-day moving average. The market capitalization of the company currently stands at $242.63M.
There are 1 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $9.50 as their price target over the next twelve months.
With the price target reduced from $11 to $2, Stephens Downgraded its rating from Overweight to Equal-Weight for Lifecore Biomedical Inc. (NASDAQ: LFCR).
In other news, WYNNEFIELD PARTNERS SMALL CAP , 10% Owner bought 345,260 shares of the company’s stock on Nov 25. The stock was bought for $2,751,722 at an average price of $7.97. Upon completion of the transaction, the 10% Owner now directly owns 1,972,853 shares in the company, valued at $15.53 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 25, 10% Owner WYNNEFIELD PARTNERS SMALL CAP bought 282,486 shares of the business’s stock. A total of $2,251,413 was incurred on buying the stock at an average price of $7.97. This leaves the insider owning 2,438,180 shares of the company worth $19.19 million. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LFCR stock. A new stake in Lifecore Biomedical Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $2,956,000. MARSHALL WACE, LLP invested $1,000,000 in shares of LFCR during the first quarter. In the first quarter, JANE STREET GROUP, LLC acquired a new stake in Lifecore Biomedical Inc. valued at approximately $747,000. DCF ADVISERS, LLC acquired a new stake in LFCR for approximately $689,000. CITADEL ADVISORS LLC purchased a new stake in LFCR valued at around $538,000 in the second quarter. In total, there are 115 active investors with 88.60% ownership of the company’s stock.
Friday morning saw Lifecore Biomedical Inc. (NASDAQ: LFCR) opened at $8.00. During the past 12 months, Lifecore Biomedical Inc. has had a low of $1.52 and a high of $11.45. As of last week, the company has a debt-to-equity ratio of 3.36, a current ratio of 2.30, and a quick ratio of 1.10. The fifty day moving average price for LFCR is $9.62 and a two-hundred day moving average price translates $7.00 for the stock.
The latest earnings results from Lifecore Biomedical Inc. (NASDAQ: LFCR) was released for Feb, 2023. The net profit margin was -84.20% and return on equity was -124.40% for LFCR. The company reported revenue of $27.6 million for the quarter, compared to $37.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -26.2 percent.
Lifecore Biomedical Inc.(LFCR) Company Profile
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is based in Chaska, Minnesota.
